[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338076-105":59,"doc-detail-338076-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","case-series-of-li-fraumeni-syndrome-carcinogenic-mechanisms-in-breast-cancer-with-tp53-pathogenic-variant-carriers","Case series of Li-Fraumeni syndrome - carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers","","Li-Fraumeni syndrome (LFS), caused by TP53 pathogenic variants, is linked to high risks of multiple malignancies, with breast cancer particularly enriched among TP53 variant carriers. This retrospective study assessed associations between TP53 variants and breast cancer phenotype, reviewing LFS patient records from a single institution and relevant TP53 literature. Among 10 patients from eight families, 9 developed breast cancer, with HER2+ subtypes representing 40% and HR−/HER2+ tumors showing a slightly earlier onset.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-series-of-li-fraumeni-syndrome-carcinogenic-mechanisms-in-breast-cancer-with-tp53-pathogenic-variant-carriers/338076/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-series-of-li-fraumeni-syndrome-carcinogenic-mechanisms-in-breast-cancer-with-tp53-pathogenic-variant-carriers/338076.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What condition underlies the study of the Li-Fraumeni case series?","Question",{"text":112,"@type":113},"Li-Fraumeni syndrome is attributed to TP53 pathogenic variants and is associated with high risks of diverse malignant tumors, including breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the association between TP53 variants and breast cancer phenotype evaluated?",{"text":117,"@type":113},"The study used a retrospective review of medical records for LFS patients treated at a single institution and supplemented it with a literature review on TP53 functions and mechanisms related to HER2+ breast cancer development.",{"name":119,"@type":110,"acceptedAnswer":120},"What proportion of breast cancers in the case series were HER2+?",{"text":121,"@type":113},"Immunohistochemical analyses showed that 40% of breast cancers in patients with LFS were HR−/HER2+.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338076,1790835035,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Breast Cancer (2024) 31:988–996  \n[https://doi.org/10.1007/s12282-024-01612-3](https://doi.org/10.1007/s12282-024-01612-3)  \nCase series of Li‑Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers  \nMari Hosonaga1 · Eri Habano2 · Hiromi Arakawa2 · Keika Kaneko2 · Takeshi Nakajima3 · Naomi Hayashi5 · Ippei Fukada1,5 · Akira Nakamura4 · Yurie Haruyama4 · Tetsuyo Maeda4 · Hitoshi Inari4 · Takayuki Kobayashi1 · Eri Nakashima4 · Takayuki Ueno4 · Toshimi Takano1 · Shunji Takahashi5 · Shinji Ohno1,4 · Arisa Ueki2  \nReceived: 27 September 2023 / Accepted: 30 June 2024 / Published online: 17 July 2024 © The Author(s) 2024  \nAbstract  \nBackground Li-Fraumeni syndrome (LFS), a hereditary condition attributed to TP53 pathogenic variants,(PV), is associated with high risks for various malignant tumors, including breast cancer. Notably, individuals harboring TP53 PVs are more likely (67–83%) to develop HER2 + breast cancer than noncarriers (16–25%) . In this retrospective study, we evaluated the associations between TP53 variants and breast cancer phenotype.  \nMethods We conducted a retrospective review of the medical records of patients with LFS treated at a single institution and reviewed the literature on TP53 functions and the mechanisms underlying HER2 + breast cancer development in LFS. Results We analyzed data for 10 patients with LFS from 8 families. The median age at the onset of the first tumor was 35.5 years. Only case 2 met the classic criteria; this patient harbored a nonsense variant, whereas the other patients carried missense variants. We observed that 9 of 10 patients developed breast cancer. Immunohistochemical analyses revealed that 40% of breast cancers in patients with LFS were HR − /HER2 + . The median age at the onset of breast cancer was slightly younger in HR − /HER2 + tumors than in HR + /HER2 − tumors (31 years and 35.5 years, respectively) .  \nConclusions The occurrence of HER2 + breast cancer subtype was 40% in our LFS case series, which is greater than that in the general population (16–25%) . Some TP53 PVs may facilitate HER2-derived oncogenesis in breast cancer. However, further studies with larger sample sizes are warranted to clarify the oncogenic mechanisms underlying each subtype of breast cancer in TP53 PV carriers.  \nKeywords Li-Fraumeni syndrome · TP53 · Breast cancer · Hormone receptor · Human epidermal growth factor receptor 2  \n* Mari Hosonaga [mari.hosonaga@jfcr.or.jp](mari.hosonaga@jfcr.or.jp)  \n1 Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan  \n2 Department of Clinical Genetic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan  \n3 Medical Ethics and Medical Genetics, Kyoto University, Graduate of School of Medicine, School of Public Health, Kyoto 606-8501, Japan  \n4 Department of Breast Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan  \n5 Division of Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan  \nIntroduction  \nTP53 and Li‑Fraumeni syndrome  \nTumor protein P53 (TP53) expression is induced by various physiological stresses, such as DNA damage, radiation, hypoxia, and oncogene signaling. TP53 functions as a guardian of the genome by inducing apoptosis and preventing the accumulation of genomic mutations in cells [1, 2] . Somatic pathogenic variants in TP53 are found in 18–50% of all malignant tumors in humans [3, 4], suggesting that TP53 isan early oncogenic driver in various types of cancers.  \nThe p53 protein functions as a tumor suppressor primarily by binding to p53 DNA-binding sites in its target genes to regulate their expression [5] . TP53 pathogenic variants (PVs), both germline and somatic, are primarily distributed  \nin the DNA-binding domain and impair TP53 transcription [6] .  \nLi-Fraumeni syndro","cbCaiu6zwY0MnOtk","https://ap.wps.com/l/cbCaiu6zwY0MnOtk","pdf",778930,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## TP53 and Li-Fraumeni syndrome\n## Role of TP53 in breast cancer development","[{\"question\":\"What condition underlies the study of the Li-Fraumeni case series?\",\"answer\":\"Li-Fraumeni syndrome is attributed to TP53 pathogenic variants and is associated with high risks of diverse malignant tumors, including breast cancer.\"},{\"question\":\"How was the association between TP53 variants and breast cancer phenotype evaluated?\",\"answer\":\"The study used a retrospective review of medical records for LFS patients treated at a single institution and supplemented it with a literature review on TP53 functions and mechanisms related to HER2+ breast cancer development.\"},{\"question\":\"What proportion of breast cancers in the case series were HER2+?\",\"answer\":\"Immunohistochemical analyses showed that 40% of breast cancers in patients with LFS were HR−/HER2+.\"}]","Case series of Li-Fraumeni syndrome - carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers | PDF",1790021849,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aadeb9bc849600cc4d7323cd732ab5dd.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58d87b38416aaa30f1b2f550cc37c601.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6508db8f11141974bfc3a7d79a5f345d.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46014aadb25c1d7bf26f3eb52528e127.webp",980,1301]